BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6911148)

  • 1. Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen.
    Sundsmo JS; Wood LM
    J Immunol; 1981 Sep; 127(3):877-80. PubMed ID: 6911148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading.
    Sundsmo JS; Götze O
    J Exp Med; 1981 Sep; 154(3):763-77. PubMed ID: 6912276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
    Lawrie CH; Sim RB; Nuttall PA
    Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the initial C3 convertase of the alternative pathway of human complement.
    Fishelson Z; Pangburn MK; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1430-4. PubMed ID: 6559201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alternative pathway C3/C5 convertase: chemical basis of factor B activation.
    Lesavre PH; Hugli TE; Esser AF; Müller-Eberhard HJ
    J Immunol; 1979 Aug; 123(2):529-34. PubMed ID: 458145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of alternative pathway factor D by factor B-related synthetic hexapeptides.
    Lesavre P; Gaillard MH; Halbwachs-Mecarelli L
    Eur J Immunol; 1982 Mar; 12(3):252-4. PubMed ID: 6920299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fibrinogenolytic activity of purified tryptase from human lung mast cells.
    Schwartz LB; Bradford TR; Littman BH; Wintroub BU
    J Immunol; 1985 Oct; 135(4):2762-7. PubMed ID: 3161948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent linkage of C3 to properdin during complement activation.
    Whiteman LY; Purkall DB; Ruddy S
    Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a major serum DNA-binding protein as factor B of the alternative complement pathway.
    Gardner WD; Haselby JA; Hoch SO
    J Immunol; 1980 Jun; 124(6):2800-6. PubMed ID: 6989908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.
    Lambris JD; Müller-Eberhard HJ
    J Biol Chem; 1984 Oct; 259(20):12685-90. PubMed ID: 6567645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of a proteinase with plasminogen-activating activity from Lachesis muta muta (bushmaster) snake venom.
    Sanchez EF; Santos CI; Magalhaes A; Diniz CR; Figueiredo S; Gilroy J; Richardson M
    Arch Biochem Biophys; 2000 Jun; 378(1):131-41. PubMed ID: 10871053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of chrysotile asbestos fibres with the complement system.
    Saint-Remy JM; Cole P
    Immunology; 1980 Oct; 41(2):431-7. PubMed ID: 6904360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.